BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1226 related articles for article (PubMed ID: 22849944)

  • 1. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.
    Bieze M; van den Esschert JW; Nio CY; Verheij J; Reitsma JB; Terpstra V; van Gulik TM; Phoa SS
    AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
    Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
    Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
    Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
    Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.
    Agarwal S; Fuentes-Orrego JM; Arnason T; Misdraji J; Jhaveri KS; Harisinghani M; Hahn PF
    AJR Am J Roentgenol; 2014 Oct; 203(4):W408-14. PubMed ID: 25055198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI.
    Péporté AR; Sommer WH; Nikolaou K; Reiser MF; Zech CJ
    Eur J Radiol; 2013 Mar; 82(3):e101-6. PubMed ID: 23159401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review.
    Guo Y; Li W; Cai W; Zhang Y; Fang Y; Hong G
    Int J Med Sci; 2017; 14(7):668-674. PubMed ID: 28824299
    [No Abstract]   [Full Text] [Related]  

  • 14. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.
    Suh CH; Kim KW; Kim GY; Shin YM; Kim PN; Park SH
    Eur Radiol; 2015 Apr; 25(4):950-60. PubMed ID: 25537979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
    Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
    Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial.
    Zech CJ; Grazioli L; Breuer J; Reiser MF; Schoenberg SO
    Invest Radiol; 2008 Jul; 43(7):504-11. PubMed ID: 18580333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
    Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion weighted imaging of liver lesions suspect for metastases: Apparent diffusion coefficient (ADC) values and lesion contrast are independent from Gd-EOB-DTPA administration.
    Benndorf M; Schelhorn J; Dietzel M; Kaiser WA; Baltzer PA
    Eur J Radiol; 2012 Aug; 81(8):e849-53. PubMed ID: 22575171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.